GSK598809
GSK598809 is a pharmaceutical drug with 8 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
75.0%
6 of 8 finished
25.0%
2 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809
A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers
Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809
A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward
EtOH Interaction Study
Clinical Trials (8)
A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809
A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers
Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809
A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward
EtOH Interaction Study
Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention
Relapse Prevention Study in Newly Abstinent Smokers
Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8